SCHEMBL320304

SCHEMBL320304

Cc1nc2ccc(C(=O)c3c(C)c(Br)c4ccccn34)cc2c(=O)[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
HPGD P15428 3/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 2/20 0.43
IP6K1 Q92551 1/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 2/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
USP2 O75604 1/20 0.42
GLA P06280 1/20 0.42
HSD17B10 Q99714 2/20 0.42
HTT P42858 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
PARP1 P09874 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
ACVR1 Q04771 2/20 0.41
LMNA P02545 2/20 0.40
KMT2A Q03164 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321154 0.86 LMNA (0.46) ALDH1A1HPGDRAB9ASMN1; SMN2POLB
SCHEMBL320647 0.82 ALDH1A1 (0.41) ALDH1A1HPGDRAB9ASMN1; SMN2POLB
SCHEMBL27922041 0.80 PDE5A (0.41) ALDH1A1HPGDRAB9ASMN1; SMN2POLB
SCHEMBL320837 0.80 MAPT (0.41) ALDH1A1HPGDRAB9ASMN1; SMN2POLB
SCHEMBL16340821 0.74 HTT (0.39) ALDH1A1HPGDSMN1; SMN2KDM4EGAA
SCHEMBL11005432 0.74 HTT (0.47) ALDH1A1HPGDSMN1; SMN2POLBKDM4E
SCHEMBL320949 0.72 HTT (0.46) ALDH1A1HPGDPOLBKDM4EGAA
SCHEMBL15067929 0.72 MAPT (0.42) ALDH1A1HPGDRAB9ASMN1; SMN2KDM4E
SCHEMBL30864305 0.71 TDP1 (0.67) ALDH1A1HPGDRAB9ASMN1; SMN2POLB
SCHEMBL15017204 0.71 KDM4E (0.39) ALDH1A1HPGDSMN1; SMN2POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 ALDH1A1 3536/4885HPGD 810/4885RAB9A 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.